Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Two pharmaceutical companies based in India were charged Monday with smuggling chemicals used in the production of the deadly drug fentanyl, federal prosecutors in New York ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Viking Therapeutics (VKTX) is identified by Oppenheimer among five potential biotech M&A candidates ahead of J.P. Morgan Healthcare Conference. Read more here.

Academics are calling for governments to act to “safeguard the ind | Academics are calling for governments to act to ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...

Pharmaceutical companies are raising the price of over 250 brand drugs this year. Nearly all the price increases are under 10 ...

Everything from a new player-owned basketball league to a self-driving car service made headlines as the year wraps up.